◼ Archived
Health
🔮 fades ✓
Study reveals new role for tau, a top target for Alzheimer’s drug development
New research on tau protein may transform Alzheimer’s treatment and diagnosis
Biogen
4 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Biogen
This hub groups 4 separate news trends connected to Biogen, spanning July 14, 2026 through August 7, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 31 article observations and 29 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✗
Alzheimer's: Real-world study confirms Leqembi therapy benefits
FDA approval of an at-home subcutaneous starter dose for Leqembi coincides with a real-world study confirming the therapy's benefits.
◼ Archived
Business
🔮 fades ✗
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches
Biogen’s experimental tau-targeting Alzheimer’s drug sparks industry debate following mixed clinical trial results.
◼ Archived
Business
🔮 fades ✓
All eyes on data on Biogen’s tau therapy
Biogen's experimental anti-tau therapy, diranersen, shows promise in slowing cognitive decline for early Alzheimer's patients.